Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients

Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipients on immunosup...

Full description

Saved in:
Bibliographic Details
Published in:Dermatology Research and Practice 2014-01, Vol.2014 (2014), p.67-72
Main Authors: Popoola, Joyce, Quante, Mara, Williams, Sion K., Dobson, Joelle S., Roche, Christopher D., Chow, Jade W. M.
Format: Article
Language:English
Subjects:
Diagnosis
Health aspects
Immunotherapy
Kidneys
Melanoma
Organ transplant recipients
Prevention
Transplantation
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-a656t-c331bacc6f720ceea79216e5c166d84cd857352278de13a374a764e5bb2c28ed3
container_end_page 72
container_issue 2014
container_start_page 67
container_title Dermatology Research and Practice
container_volume 2014
creator Popoola, Joyce
Quante, Mara
Williams, Sion K.
Dobson, Joelle S.
Roche, Christopher D.
Chow, Jade W. M.
description Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipients on immunosuppression at our hospital from 1995 to 2008. Skin tumours were recorded/analysed. Results. Mean age at transplant was 46 years. Mean length of follow-up was 7.2 years and total follow-up was 4926 person-years. 53 (7.5%) patients (39/458 (8.5%) males and 14/251 (5.6%) females) developed ≥1 skin malignancy. Cumulative incidences of 4.0%, 7.5%, and 12.2% were observed for those with
doi_str_mv 10.1155/2014/409058
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_f6c6184de1e544539bb8041635a35300</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A413708997</galeid><airiti_id>P20151208002_201412_201512080002_201512080002_67_72</airiti_id><doaj_id>oai_doaj_org_article_f6c6184de1e544539bb8041635a35300</doaj_id><sourcerecordid>A413708997</sourcerecordid><originalsourceid>FETCH-LOGICAL-a656t-c331bacc6f720ceea79216e5c166d84cd857352278de13a374a764e5bb2c28ed3</originalsourceid><addsrcrecordid>eNqNkl1v0zAUhiMEYmNwxT2KhIQQqJu_7dxMmqYBQ-NDo1xbJ47TuiR2iZMi_j1uU7p24gLlwvbJc57Er06WPcfoFGPOzwjC7IyhAnH1IDvGQsmJwJg-3O0RP8qexLhASCBG1OPsiHCKCBL0OLv6BI2befB9Dr7KPwfv_AqiW9n82w_n8-nQhqGLedreWg9NPu3Ax2Wzbri1xi2d9X18mj2qoYn22XY9yb6_u5pefpjcfHl_fXlxMwHBRT8xlOISjBG1JMhYC7IgWFhusBCVYqZSXFJOiFSVxRSoZCAFs7wsiSHKVvQkux69VYCFXnauhe63DuD0phC6mYaud6axuhZGYMWSyHLGOC3KUiGGBeVA0-1Rcp2PruVQtrYy6R4dNAfSwzfezfUsrDTDCtFCJMHrraALPwcbe926aGyTsrFhiBqn5KVIqEroy3voIqWa4kyURAWRFDF2R80gXcD5OqTvmrVUXzBMJVJFIRN1-g8qPZVtnQne1i7VDxpe7TXMLTT9PIZm6F3w8RB8O4KmCzF2tt6FgZFej5pej5oeRy3RL_bz27F_ZysBb0Zg7nwFv9z_2WxCbA17cIqbrX_u4wiA61zv7gL8mjQcE6QQIhsl3izbErp3EFJLQv8AbQf0xA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1709273044</pqid></control><display><type>article</type><title>Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Popoola, Joyce ; Quante, Mara ; Williams, Sion K. ; Dobson, Joelle S. ; Roche, Christopher D. ; Chow, Jade W. M.</creator><contributor>Kanitakis, Jean</contributor><creatorcontrib>Popoola, Joyce ; Quante, Mara ; Williams, Sion K. ; Dobson, Joelle S. ; Roche, Christopher D. ; Chow, Jade W. M. ; Kanitakis, Jean</creatorcontrib><description>Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipients on immunosuppression at our hospital from 1995 to 2008. Skin tumours were recorded/analysed. Results. Mean age at transplant was 46 years. Mean length of follow-up was 7.2 years and total follow-up was 4926 person-years. 53 (7.5%) patients (39/458 (8.5%) males and 14/251 (5.6%) females) developed ≥1 skin malignancy. Cumulative incidences of 4.0%, 7.5%, and 12.2% were observed for those with &lt;5, &lt;10, and ≥10 years follow-up, respectively. The rate was 45 tumours per 1000 person-years at risk. Additionally, 21 patients (3.0%) only had noninvasive tumours. 221 malignant skin tumours were found: 50.2% were SCCs, 47.1% BCCs, and 2.7% malignant melanomas. Mean years to first tumour were 5.8. Mean number of tumours per patient was 4, with mean interval of 12 months. Conclusions. Despite changes in transplantation practice during the time since the last data were published in this region, these findings are similar to previous studies. This adds to the evidence allowing clinicians to inform patients in this region of their risk.</description><identifier>ISSN: 1687-6105</identifier><identifier>EISSN: 1687-6113</identifier><identifier>DOI: 10.1155/2014/409058</identifier><identifier>PMID: 25302063</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Diagnosis ; Health aspects ; Immunotherapy ; Kidneys ; Melanoma ; Organ transplant recipients ; Prevention ; Transplantation</subject><ispartof>Dermatology Research and Practice, 2014-01, Vol.2014 (2014), p.67-72</ispartof><rights>Copyright © 2014 Christopher D. Roche et al.</rights><rights>COPYRIGHT 2014 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2014 Christopher D. Roche et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2014 Christopher D. Roche et al. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-a656t-c331bacc6f720ceea79216e5c166d84cd857352278de13a374a764e5bb2c28ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1709273044/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1709273044?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25302063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kanitakis, Jean</contributor><creatorcontrib>Popoola, Joyce</creatorcontrib><creatorcontrib>Quante, Mara</creatorcontrib><creatorcontrib>Williams, Sion K.</creatorcontrib><creatorcontrib>Dobson, Joelle S.</creatorcontrib><creatorcontrib>Roche, Christopher D.</creatorcontrib><creatorcontrib>Chow, Jade W. M.</creatorcontrib><title>Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients</title><title>Dermatology Research and Practice</title><addtitle>Dermatol Res Pract</addtitle><description>Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipients on immunosuppression at our hospital from 1995 to 2008. Skin tumours were recorded/analysed. Results. Mean age at transplant was 46 years. Mean length of follow-up was 7.2 years and total follow-up was 4926 person-years. 53 (7.5%) patients (39/458 (8.5%) males and 14/251 (5.6%) females) developed ≥1 skin malignancy. Cumulative incidences of 4.0%, 7.5%, and 12.2% were observed for those with &lt;5, &lt;10, and ≥10 years follow-up, respectively. The rate was 45 tumours per 1000 person-years at risk. Additionally, 21 patients (3.0%) only had noninvasive tumours. 221 malignant skin tumours were found: 50.2% were SCCs, 47.1% BCCs, and 2.7% malignant melanomas. Mean years to first tumour were 5.8. Mean number of tumours per patient was 4, with mean interval of 12 months. Conclusions. Despite changes in transplantation practice during the time since the last data were published in this region, these findings are similar to previous studies. This adds to the evidence allowing clinicians to inform patients in this region of their risk.</description><subject>Diagnosis</subject><subject>Health aspects</subject><subject>Immunotherapy</subject><subject>Kidneys</subject><subject>Melanoma</subject><subject>Organ transplant recipients</subject><subject>Prevention</subject><subject>Transplantation</subject><issn>1687-6105</issn><issn>1687-6113</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl1v0zAUhiMEYmNwxT2KhIQQqJu_7dxMmqYBQ-NDo1xbJ47TuiR2iZMi_j1uU7p24gLlwvbJc57Er06WPcfoFGPOzwjC7IyhAnH1IDvGQsmJwJg-3O0RP8qexLhASCBG1OPsiHCKCBL0OLv6BI2befB9Dr7KPwfv_AqiW9n82w_n8-nQhqGLedreWg9NPu3Ax2Wzbri1xi2d9X18mj2qoYn22XY9yb6_u5pefpjcfHl_fXlxMwHBRT8xlOISjBG1JMhYC7IgWFhusBCVYqZSXFJOiFSVxRSoZCAFs7wsiSHKVvQkux69VYCFXnauhe63DuD0phC6mYaud6axuhZGYMWSyHLGOC3KUiGGBeVA0-1Rcp2PruVQtrYy6R4dNAfSwzfezfUsrDTDCtFCJMHrraALPwcbe926aGyTsrFhiBqn5KVIqEroy3voIqWa4kyURAWRFDF2R80gXcD5OqTvmrVUXzBMJVJFIRN1-g8qPZVtnQne1i7VDxpe7TXMLTT9PIZm6F3w8RB8O4KmCzF2tt6FgZFej5pej5oeRy3RL_bz27F_ZysBb0Zg7nwFv9z_2WxCbA17cIqbrX_u4wiA61zv7gL8mjQcE6QQIhsl3izbErp3EFJLQv8AbQf0xA</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Popoola, Joyce</creator><creator>Quante, Mara</creator><creator>Williams, Sion K.</creator><creator>Dobson, Joelle S.</creator><creator>Roche, Christopher D.</creator><creator>Chow, Jade W. M.</creator><general>Hindawi Limiteds</general><general>Hindawi Publishing Corporation</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20140101</creationdate><title>Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients</title><author>Popoola, Joyce ; Quante, Mara ; Williams, Sion K. ; Dobson, Joelle S. ; Roche, Christopher D. ; Chow, Jade W. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a656t-c331bacc6f720ceea79216e5c166d84cd857352278de13a374a764e5bb2c28ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Diagnosis</topic><topic>Health aspects</topic><topic>Immunotherapy</topic><topic>Kidneys</topic><topic>Melanoma</topic><topic>Organ transplant recipients</topic><topic>Prevention</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Popoola, Joyce</creatorcontrib><creatorcontrib>Quante, Mara</creatorcontrib><creatorcontrib>Williams, Sion K.</creatorcontrib><creatorcontrib>Dobson, Joelle S.</creatorcontrib><creatorcontrib>Roche, Christopher D.</creatorcontrib><creatorcontrib>Chow, Jade W. M.</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database (ProQuest)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Dermatology Research and Practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Popoola, Joyce</au><au>Quante, Mara</au><au>Williams, Sion K.</au><au>Dobson, Joelle S.</au><au>Roche, Christopher D.</au><au>Chow, Jade W. M.</au><au>Kanitakis, Jean</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients</atitle><jtitle>Dermatology Research and Practice</jtitle><addtitle>Dermatol Res Pract</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>2014</volume><issue>2014</issue><spage>67</spage><epage>72</epage><pages>67-72</pages><issn>1687-6105</issn><eissn>1687-6113</eissn><abstract>Transplant recipients require immunosuppression to prevent graft rejection. This conveys an increased risk of malignancy, particularly skin tumours. There is a need for up-to-date data for the South of England. Method. Pathology records were reviewed for 709 kidney transplant recipients on immunosuppression at our hospital from 1995 to 2008. Skin tumours were recorded/analysed. Results. Mean age at transplant was 46 years. Mean length of follow-up was 7.2 years and total follow-up was 4926 person-years. 53 (7.5%) patients (39/458 (8.5%) males and 14/251 (5.6%) females) developed ≥1 skin malignancy. Cumulative incidences of 4.0%, 7.5%, and 12.2% were observed for those with &lt;5, &lt;10, and ≥10 years follow-up, respectively. The rate was 45 tumours per 1000 person-years at risk. Additionally, 21 patients (3.0%) only had noninvasive tumours. 221 malignant skin tumours were found: 50.2% were SCCs, 47.1% BCCs, and 2.7% malignant melanomas. Mean years to first tumour were 5.8. Mean number of tumours per patient was 4, with mean interval of 12 months. Conclusions. Despite changes in transplantation practice during the time since the last data were published in this region, these findings are similar to previous studies. This adds to the evidence allowing clinicians to inform patients in this region of their risk.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>25302063</pmid><doi>10.1155/2014/409058</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1687-6105
ispartof Dermatology Research and Practice, 2014-01, Vol.2014 (2014), p.67-72
issn 1687-6105
1687-6113
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_f6c6184de1e544539bb8041635a35300
source Wiley Online Library Open Access; Publicly Available Content Database; PubMed Central
subjects Diagnosis
Health aspects
Immunotherapy
Kidneys
Melanoma
Organ transplant recipients
Prevention
Transplantation
title Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T22%3A08%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Malignant%20and%20Noninvasive%20Skin%20Tumours%20in%20Renal%20Transplant%20Recipients&rft.jtitle=Dermatology%20Research%20and%20Practice&rft.au=Popoola,%20Joyce&rft.date=2014-01-01&rft.volume=2014&rft.issue=2014&rft.spage=67&rft.epage=72&rft.pages=67-72&rft.issn=1687-6105&rft.eissn=1687-6113&rft_id=info:doi/10.1155/2014/409058&rft_dat=%3Cgale_doaj_%3EA413708997%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a656t-c331bacc6f720ceea79216e5c166d84cd857352278de13a374a764e5bb2c28ed3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1709273044&rft_id=info:pmid/25302063&rft_galeid=A413708997&rft_airiti_id=P20151208002_201412_201512080002_201512080002_67_72&rfr_iscdi=true